Clinical Trial Update: A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet [Phase 1]

View source ↗

Summary

A Phase 1 bioavailability study of a prasugrel orally disintegrating tablet in sickle cell disease, with the trial status completed and results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Prasugrel ODT (prasugrel)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED | Results posted: 2012-11-06